The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Cg Oncology Inc (NASDAQ: CGON) was $42.61 for the day, up 3.00% from the previous closing price of $41.37. In other words, the price has increased by $3.00 from its previous closing price. On the day, 1.05 million shares were traded. CGON stock price reached its highest trading level at $43.0 during the session, while it also had its lowest trading level at $41.24.
Ratios:
Our analysis of CGON’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 22.74 and its Current Ratio is at 22.79. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On October 08, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $90.
On August 19, 2025, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $55.Piper Sandler initiated its Overweight rating on August 19, 2025, with a $55 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 17 ’25 when POST LEONARD E sold 1,000 shares for $41.43 per share. The transaction valued at 41,430 led to the insider holds 0 shares of the business.
POST LEONARD E sold 1,000 shares of CGON for $43,250 on Oct 13 ’25. The Director now owns 0 shares after completing the transaction at $43.25 per share. On Oct 09 ’25, another insider, Mulay James, who serves as the Director of the company, sold 5,903 shares for $43.99 each. As a result, the insider received 259,673 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGON now has a Market Capitalization of 3437185792 and an Enterprise Value of 2764163840. For the stock, the TTM Price-to-Sale (P/S) ratio is 1583.96 while its Price-to-Book (P/B) ratio in mrq is 4.85. Its current Enterprise Value per Revenue stands at 1271.465 whereas that against EBITDA is -15.397.
Stock Price History:
The Beta on a monthly basis for CGON is 1.36, which has changed by 0.23271751 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, CGON has reached a high of $45.94, while it has fallen to a 52-week low of $14.80. The 50-Day Moving Average of the stock is 3.03%, while the 200-Day Moving Average is calculated to be 41.91%.
Shares Statistics:
CGON traded an average of 1.03M shares per day over the past three months and 777590 shares per day over the past ten days. A total of 78.28M shares are outstanding, with a floating share count of 48.93M. Insiders hold about 39.34% of the company’s shares, while institutions hold 76.87% stake in the company. Shares short for CGON as of 1763078400 were 13205390 with a Short Ratio of 12.81, compared to 1760486400 on 12222593. Therefore, it implies a Short% of Shares Outstanding of 13205390 and a Short% of Float of 17.28.
Earnings Estimates
The market rating for Cg Oncology Inc (CGON) is a result of the insights provided by 11.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.57 and low estimates of -$0.7.
Analysts are recommending an EPS of between -$1.82 and -$2.24 for the fiscal current year, implying an average EPS of -$2.11. EPS for the following year is -$2.57, with 11.0 analysts recommending between -$1.41 and -$3.33.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for CGON’s current fiscal year. The highest revenue estimate was $9.45M, while the lowest revenue estimate was $1.7M, resulting in an average revenue estimate of $2.87M. In the same quarter a year ago, actual revenue was $1.14M
